Trade Info : Orchid Pharma gets court approval to merge with Dhanuka Laboratories

Symbol

ORCHPHARMA

Company

Orchid Pharma Ltd

Category

Promoter Update

Source

Stock Exchange Filing

Total Sales Target

1400-1500 crores

EBITDA Target

200-250 crores

Dhanuka Shareholders Receiving

161 shares

Old Shares Surrendered

5 shares

News Summary

The National Company Law Tribunal approved the merger of Dhanuka Laboratories into Orchid Pharma on June 5, 2026.
This legal order confirms the plan to combine the two companies into one larger entity.
Shareholders of Dhanuka will receive new Orchid Pharma shares once the merger officially starts.

Why This Matters

This means the two companies will now operate as a single, bigger business with more resources.
As a result, investors in Orchid Pharma may see improved efficiency and a stronger market position.
Investors should know that the smaller company is disappearing and its owners will get new shares.

Fundamental Backdrop (FY – FY )

Metric	Value
Number of New Shares for Dhanuka Shareholders	161
Old Shares Given Up for Each New Share	5
Face Value of New Share	10 Rupees
Face Value of Old Share	100 Rupees

Analyst's View

This suggests the company is taking a major step to become larger and more competitive.
The company appears to be combining operations to save costs and reach more customers.
Investors may want to watch how the new combined business performs in the coming months.

Buy

Confidence 85%

Conviction Level 85%

The court has officially approved the merger, which creates a larger and stronger company for existing shareholders.

Key Positives

The merger creates a larger company with more sales potential and better market reach.
Combining operations will reduce costs and eliminate duplicate work between the two firms.
Shareholders of the smaller company will own a piece of the new, larger Orchid Pharma.

Key Risks

Integrating two different companies can be difficult and might slow down operations temporarily.
The tax authorities have reserved their right to review the deal later for any tax issues.
Some bank loans on the smaller company have unclear details that need to be fixed.

HorizonMedium term

Confidence LevelHigh

Suggested position size: Increase position gradually over the next 3 to 6 months

⚠️

Disclaimer This analysis is for informational purposes only and does not constitute financial advice. Do your own research and consult a qualified financial professional before making any investment decisions.